Healthcare services group Uniphar has reported higher profit and revenues for the six months to the end of June and said it remained confident of reaching its target of €200m EBITDA by 2028.
Profits before tax rose by 22.5% to €28.7m from €23.43m the same time last year, while its revenues increased by 8.6% to €1.485 billion from €1.367 billion.
Uniphar, which owns pharmacy chains including Allcare and Hickeys, said its EBITDA for the six month period rose by 2.9% to €57.495m from €55.90m.
The company's adjusted earnings per cent jumped by 21% to 9.8 cent from 8.1 cent, which it said reflected underlying business growth together with the positive impact of lower finance costs and the share buyback.
A share buyback programme of €35m was completed in the six month period with 13.4 million shares repurchased, it noted.
The Uniphar board has declared an interim dividend of €0.0071 per ordinary share for the six month period, representing growth of 6% on the same time last year.
Ger Rabbette, Uniphar Group's chief executive, said the company delivered a strong performance in the first half of 2025 with adjusted EPS growth of 21% and organic gross profit growth of 8.1% with each division delivering in-line with their medium-term targets.
"Our uncompromising focus on solving our healthcare clients' challenges, together with our strategic investment programme, further enhances our capability to deliver strong organic growth into the future," the CEO said.
"We remain confident of achieving our target of €200m EBITDA by 2028 with at least 80% of that growth being delivered organically," he added.
Shares in the company moved higher in Dublin trade today.
